Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Usanova, Svetlana ^a   Piée Staffa, Andrea ^a   Sied, Ulrike ^a   Thomale, Jürgen ^b   Schneider, Astrid ^a,c   Kaina, Bernd ^a   Köberle, Beate ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^c NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GAMMA HISTONE H2AX; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ANIMAL CELL; ARTICLE; BLADDER CANCER; CANCER RESISTANCE; CONTROLLED STUDY; CPG ISLAND; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DNA TRANSFECTION; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MALE; MARKER GENE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TESTIS TUMOR; TUMOR CELL; ANIMAL; APOPTOSIS; BLADDER TUMOR; CHO CELL; CRICETULUS; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HAMSTER; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CHO CELLS; CISPLATIN; CRICETINAE; CRICETULUS; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 77956608305     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-248     Document Type: Article

References (37)

1. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006, 367:754-765. 10.1016/S0140-6736(06)68305-0, 16517276.
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
3. Masters JRW, Osborne EJ, Walker MC, Parris CN. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int J Cancer 1993, 53:340-346. 10.1002/ijc.2910530228, 8425772.
4. Masters JR, Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Rev Cancer 2003, 3:517-525.
5. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 1986, 25:3912-3915. 10.1021/bi00361a026, 3741840.
6. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. The Lancet Oncology 2001, 2:483-490. 10.1016/S1470-2045(01)00454-5, 11905724.
7. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110:352-361. 10.1002/ijc.20134, 15095299.
8. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997, 70:551-555. 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G, 9052754.
9. Liedert B, Pluim D, Schellens J, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006, 34:e47. 10.1093/nar/gkl051, 1420801, 16571898.
10. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002, 30:3848-3856. 10.1093/nar/gkf479, 137407, 12202770.
11. Wood R, Burki HJ. Repair capability and the cellular age response for killing and mutation induction after UV. Mutat Res 1982, 95:505-514.
12. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008, 76:19-27. 10.1016/j.bcp.2008.03.025, 18508035.
13. Siddik ZH. Cisplatin: mode of action and molecular basis of resistance. Oncogene 2003, 22:7265-7279. 10.1038/sj.onc.1206933, 14576837.
14. Pabla N, Huang S, Mi Q-S, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008, 283:6572-6583. 10.1074/jbc.M707568200, 18162465.
15. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J. Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell 2009, 35:704-715. 10.1016/j.molcel.2009.08.014, 2756577, 19748363.
16. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH, Kanaar R. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004, 24:5776-5787. 10.1128/MCB.24.13.5776-5787.2004, 480908, 15199134.
17. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei Y-F, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996, 86:811-822. 10.1016/S0092-8674(00)80155-5, 8797827.
18. Yagi T, Matsumura Y, Sato M, Nishigori C, Mori T, Sijbers AM, Takebe H. Complete restoration of normal DNA repair characteristics in group F xeroderma pigmentosum cells by over-expression of transfected XPF cDNA. Carcinogenesis 1998, 19:55-60. 10.1093/carcin/19.1.55, 9472693.
19. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006, 12:440-450. 10.1016/j.molmed.2006.07.007, 16899408.
20. Köberle B, Roginskaya V, Zima KS, Masters JR, Wood RD. Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog 2008, 47:580-586. 10.1002/mc.20418, 18240296.
21. Köberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9:273-276. 10.1016/S0960-9822(99)80118-3, 10074455.
22. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD. Repair of an interstrand DNA crosslink initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000, 275:26632-26636. 10.1074/jbc.C000337200, 10882712.
23. Köberle B, Roginskaya V, Wood RD. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells. DNA Repair 2006, 5:641-648. 10.1016/j.dnarep.2005.12.001, 16413230.
24. Rademakers S, Volker M, Hoogstraten D, Nigg AL, Mone MJ, Van Zeeland AA, Hoeijmakers JH, Houtsmuller AB, Vermeulen W. Xeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions. Mol Cell Biol 2003, 23:5755-5767. 10.1128/MCB.23.16.5755-5767.2003, 166334, 12897146.
25. Mone MJ, Bernas T, Dinant C, Goedvree FA, Manders EM, Volker M, Houtsmuller AB, Hoeijmakers JH, Vermeulen W, van Driel R. In vivo dynamics of chromatin-associated complex formation in mammalian nucleotide excision repair. Proc Natl Acad Sci USA 2004, 101:15933-15937. 10.1073/pnas.0403664101, 528744, 15520397.
26. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000, 20:645-652.
27. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000, 60:1305-1313. 10.1016/S0006-2952(00)00441-X, 11008124.
28. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
29. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
30. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991. 10.1056/NEJMoa060570, 16957145.
31. Köberle B, Tomicic M, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. BBA Reviews on Cancer 2010,
32. Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med 2005, 11:503-511. 10.1016/j.molmed.2005.09.004, 16214418.
33. Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007, 43:1791-1801. 10.1016/j.ejca.2007.05.003, 17588740.
34. Ding J, Miao Z-H, Meng L-H, Geng M-Y. Emerging cancer therapeutic opportunities target DNA repair systems. Trends Pharmacol Scl 2006, 27:338-344.
35. Kaina B, Margison G, Christmann M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cellular and Molecular Life Sciences
36. Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 1999, 59:4529-4534.
37. Gaillard PH, Wood RD. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res 2001, 29:872-879. 10.1093/nar/29.4.872, 29621, 11160918.